A three-in-one drug combo was recently found and it helps those who have a history of heart attacks find a new way to stay healthy.
In a recent clinical study led by Dr. Valentin Fuster, director of Mount Sinai in New York City, he studied roughly 2,499 patients across seven European countries.
These patients have had a history of type 1 myocardial infarction within the last six months or were over the age of 75 or had a minimum age of 65 with at least one high risk faster.
A handful of the patients were given the polypill that had aspirin, ramipril and atorvastatin while the other received typical care. The groups were followed over the next three years.
Typically after a patient suffers a heart attack, they are prescribed three different drugs. These usually are aspirin, ramipril or another drug for blood pressure and a cholesterol-lowering drug.
However, usually less than 50% of patients take their prescriptions as they are prescribed by the doctor.
“Although most patients initially adhere to treatment after an acute event such as an infarction [tissue death], adherence drops off after the first few months. Our goal was to have an impact right from the start, and most of the patients in the study began taking a simple polypill in the first week after having a heart attack”
“The results were, frankly, very exciting,” said Fuster.
After the study, the outcome was overwhelmingly positive. The results found that there was 24% reduction in heart disease or other heart problems.
The new drug also helped reveal that it helped cut the high risk of dying from cardiovascular disease by 33%.
“The SECURE study findings suggest that the polypill could become an integral element of strategies to prevent recurrent cardiovascular events in patients who have had a heart attack. By simplifying treatment and improving adherence, this approach has the potential to reduce the risk of recurrent cardiovascular disease and death on a global scale,” said Fuster.
According to UPI, the polypill that has been used within the study still hasn’t been approved by the US Food and Drug Administration. However, Fuster believes that the positive results from the study could be submitted with an effort to hopefully gain approval.
“Combination pills are easier for the physician and for the patient, and the data is pretty clear – it translates into benefit,” said Dr. Thomas Wang, chair of the department of internal medicine at UT Southwestern Medical Center.
The combination of the drugs, in this all in one pill, seems to help lead to the improvements and the patients well being, people may be more likely to stay on top of their medications to help them improve their health which is a win win.
Nikki Indelicato is a Contributing Reporter at The National Digest based in New York. You can reach her at firstname.lastname@example.org.